eli lilly tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Lilly, Novo Fight Weight Loss
Description
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
Disclaimer: Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease
Confused about where to start your metabolic health journey
Prioritize your well-being with specialized womens health services at Refined Aesthetics and Wellness in Logan, UT
consumers. | 10 comments on LinkedIn
